Niemann–Pick type C disease as proof‐of‐concept for intelligent biomarker panel selection in neurometabolic disorders. (14th July 2022)

• Record Type: Journal Article
• Authors: Papandreou, Apostolos; Doykov, Ivan; Spiewak, Justyna; Komarov, Nikita; Habermann, Stephanie; Kurian, Manju A.; Mills, Philippa B.; Mills, Kevin; Gissen, Paul; Heywood, Wendy E.
• Is Part Of: Developmental medicine & child neurology. Volume 64:Number 12(2022)
• Page Start: 1539
• Page End: 1546
• Publication Date: 2022-07-14
• Subjects: Child development -- Periodicals; Pediatric neurology -- Periodicals; 616.8
• DOI: 10.1111/dmcn.15334
• Languages: English
• ISSNs: 0012-1622

Abstract

Abstract: Aim: Using Niemann–Pick type C disease (NPC) as a paradigm, we aimed to improve biomarker discovery in patients with neurometabolic disorders. Method: Using a multiplexed liquid chromatography tandem mass spectrometry dried bloodspot assay, we developed a selective intelligent biomarker panel to monitor known biomarkers N ‐palmitoyl‐ O ‐phosphocholineserine and 3β, 5α, 6β‐trihydroxy‐cholanoyl‐glycine as well as compounds predicted to be affected in NPC pathology. We applied this panel to a clinically relevant paediatric patient cohort ( n = 75; 35 males, 40 females; mean age 7 years 6 months, range 4 days–19 years 8 months) presenting with neurodevelopmental and/or neurodegenerative pathology, similar to that observed in NPC. Results: The panel had a far superior performance compared with individual biomarkers. Namely, NPC‐related established biomarkers used individually had 91% to 97% specificity but the combined panel had 100% specificity. Moreover, multivariate analysis revealed long‐chain isoforms of glucosylceramide were elevated and very specific for patients with NPC. Interpretation: Despite advancements in next‐generation sequencing and precision medicine, neurological non‐enzymatic disorders remain difficult to diagnose and lack robust biomarkers or routine functional testing for genetic variants of unknown significance. Biomarker panels may have better diagnostic accuracy than individual biomarkers in neurometabolic disorders, hence they can facilitate more prompt disease identification and implementation of emerging targeted, disease‐specific therapies. What this paper adds: Intelligent biomarker panel design can help expedite diagnosis in neurometabolic disorders. In Niemann–Pick type C disease, such a panel performed better than individual biomarkers. Biomarker panels are easy to implement and widely applicable to neurometabolic conditions. What this paper adds: Intelligent biomarker panel design can help expedite diagnosis in neurometabolic disorders. In Niemann–Pick type C disease, such a panel performed better than individual biomarkers. Biomarker panels are easy to implement and widely applicable to neurometabolic conditions. Improved time to diagnosis for neurometabolic disorders, with Niemann Pick C (NPC) as an example, using a multiplex assay panel. Top panel displays the current scenario with diagnostic confirmation taking months and often requiring lengthy biochemical testing, especially in cases of genetic variants of unknown significance. Improved diagnosis using a bloodspot assay can achieve biochemical confirmation in 2 to 6 weeks and reduce need for subsequent biochemical confirmation after genetic diagnosis. Abbreviations: CE, clinical exome; CDH, ceramide dihexoside; DBS, dried blood spot; GlcCer, glucosylceramide; NPC, Niemann‐Pick type C; PPCS, N‐palmitoyl‐O‐phosphocholineserine; SM, sphingomyelin; WES, whole exome sequencing; WGS, whole genome sequencing. This original article is commented on by Pearl on pages 1441–1442 of this issue.